| Emma Hallab, AUD | |
|
2006 N 291 Hwy, Harrisonville, MO 64701-1224 | |
| (816) 884-4700 | |
| Not Available |
| Full Name | Emma Hallab |
|---|---|
| Gender | Female |
| Speciality | Audiologist-hearing Aid Fitter |
| Location | 2006 N 291 Hwy, Harrisonville, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184104838 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Emma Hallab, AUD 7221 W 79th St Ste 205, Overland Park, KS 66204-2978 Ph: (913) 717-4000 | Emma Hallab, AUD 2006 N 291 Hwy, Harrisonville, MO 64701-1224 Ph: (816) 884-4700 |
News Archive
Pediatric researchers at UT Southwestern Medical Center have identified a key component of the pathogenesis of bronchopulmonary dysplasia (BPD), a devastating and sometimes fatal lung disease that affects premature infants. Their findings clarify what prompts the inflammatory response that results in BPD, which previously had been unclear.
Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies.
It's a tried-and-true campaign strategy. Candidates go on the attack, claiming their opponent will do harm to Medicare. After all, people 65 and older are good about making it to the polls on Election Day. These voters are also generally motivated to protect the federal health insurance program for seniors.
AdMeTech President and CEO Dr. Faina Shtern told the U.S. House Committee on Oversight and Government Reform that a major national commitment is needed to create accurate, life-saving diagnostic tools for prostate cancer and end what she called "the prostate cancer crisis."
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
› Verified 7 days ago